Price T Rowe Associates Inc Cardiff Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 25,159 shares of CRDF stock, worth $76,231. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,159
Previous 15,390
63.48%
Holding current value
$76,231
Previous $67,000
17.91%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRDF
# of Institutions
123Shares Held
29MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$16.3 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$9.44 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$7.96 Million0.0% of portfolio
-
Blair William & CO Chicago, IL1.75MShares$5.31 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$4.38 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $131M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...